Literature DB >> 31171509

Emicizumab use in major orthopedic surgery.

Craig D Seaman1,2, Margaret V Ragni1,2.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31171509      PMCID： PMC6560352          DOI： 10.1182/bloodadvances.2019000228

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  9 in total

1.  Guidelines for the management of hemophilia.

Authors:  A Srivastava; A K Brewer; E P Mauser-Bunschoten; N S Key; S Kitchen; A Llinas; C A Ludlam; J N Mahlangu; K Mulder; M C Poon; A Street
Journal:  Haemophilia       Date:  2012-07-06       Impact factor: 4.287

2.  Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance.

Authors:  Guy Young
Journal:  Blood Adv       Date:  2018-10-23

3.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

Authors:  Johannes Oldenburg; Johnny N Mahlangu; Benjamin Kim; Christophe Schmitt; Michael U Callaghan; Guy Young; Elena Santagostino; Rebecca Kruse-Jarres; Claude Negrier; Craig Kessler; Nancy Valente; Elina Asikanius; Gallia G Levy; Jerzy Windyga; Midori Shima
Journal:  N Engl J Med       Date:  2017-07-10       Impact factor: 91.245

Review 4.  New therapies for hemophilia.

Authors:  Angela C Weyand; Steven W Pipe
Journal:  Blood       Date:  2018-12-17       Impact factor: 22.113

5.  Blood loss in total knee arthroplasty: an analysis of risk factors.

Authors:  Narayana Prasad; Vinod Padmanabhan; Arun Mullaji
Journal:  Int Orthop       Date:  2006-03-28       Impact factor: 3.075

6.  A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.

Authors:  J Teitel; E Berntorp; P Collins; R D'Oiron; B Ewenstein; E Gomperts; J Goudemand; A Gringeri; N Key; C Leissinger; P Monahan; G Young
Journal:  Haemophilia       Date:  2007-05       Impact factor: 4.287

Review 7.  Novel therapeutics for hemophilia and other bleeding disorders.

Authors:  Michael U Callaghan; Robert Sidonio; Steven W Pipe
Journal:  Blood       Date:  2018-05-16       Impact factor: 22.113

8.  Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.

Authors:  Samantha C Gouw; H Marijke van den Berg; Kathelijn Fischer; Günter Auerswald; Manuel Carcao; Elizabeth Chalmers; Hervé Chambost; Karin Kurnik; Ri Liesner; Pia Petrini; Helen Platokouki; Carmen Altisent; Johannes Oldenburg; Beatrice Nolan; Rosario Pérez Garrido; M Elisa Mancuso; Anne Rafowicz; Mike Williams; Niels Clausen; Rutger A Middelburg; Rolf Ljung; Johanna G van der Bom
Journal:  Blood       Date:  2013-04-03       Impact factor: 22.113

9.  Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors.

Authors:  L Scalone; L G Mantovani; P M Mannucci; A Gringeri
Journal:  Haemophilia       Date:  2006-03       Impact factor: 4.287
  9 in total
  7 in total

1.  Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.

Authors:  Giancarlo Castaman; Cristina Santoro; Antonio Coppola; Maria E Mancuso; Rita C Santoro; Sergio Bernardini; Francesco R Pugliese; Riccardo Lubrano; Maria Golato; Armando Tripodi; Angiola Rocino; Elena Santagostino; Chiara Biasoli; Alessandra Borchiellini; Alberto Catalano; Laura Contino; Antonella Coluccia; Dorina Cultrera; Raimondo De Cristofaro; Giovanni Di Minno; Andrea Fabbri; Massimo Franchini; Gabriella Gamba; Anna Chiara Giuffrida; Paolo Gresele; Adele Giampaolo; Hamisa J Hassan; Matteo Luciani; Emanuela Marchesini; Renato Marino; Maria Gabriella Mazzucconi; Angelo C Molinari; Massimo Morfini; Lucia D Notarangelo; Lucia Peccarisi; Flora Peyvandi; Berardino Pollio; Gianna Franca Rivolta; Maria Pia Ruggieri; Vittorio Sargentini; Mario Schiavoni; Laura Sciacovelli; Maria Luisa Serino; Sergio Siragusa; Annarita Tagliaferri; Sophie Testa; Alberto Tosetto; Stefania Zampogna; Ezio Zanon
Journal:  Blood Transfus       Date:  2019-10-18       Impact factor: 3.443

2.  Total knee replacement with and without emicizumab: a unique comparison of perioperative management.

Authors:  Matthew S Evans; Charles Davis; M Elaine Eyster
Journal:  Blood Adv       Date:  2020-03-10

3.  Management of a High-Risk Surgery with Emicizumab and Factor VIII in a Child with a Severe Hemophilia A and Inhibitor.

Authors:  Charles R Lefèvre; Anaïs Jaffré; Adeline Pontis; Fabienne Nedelec-Gac; Pierre Guéret; Isabelle Gouin-Thibault; Bernard Fraisse; Sophie Bayart; Benoit Guillet
Journal:  TH Open       Date:  2021-05-12

Review 4.  Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Paul Knoebl; Bernd Jilma
Journal:  Thromb Haemost       Date:  2020-07-27       Impact factor: 5.249

Review 5.  Bispecific Antibodies and Advances in Non-Gene Therapy Options in Hemophilia.

Authors:  Midori Shima
Journal:  Res Pract Thromb Haemost       Date:  2020-04-28

Review 6.  Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence.

Authors:  Silvia Linari; Giancarlo Castaman
Journal:  Ther Clin Risk Manag       Date:  2020-05-22       Impact factor: 2.423

7.  Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors.

Authors:  Hans H Brackmann; Wolfgang Schramm; Johannes Oldenburg; Viridiana Cano; Peter L Turecek; Claude Négrier
Journal:  Hamostaseologie       Date:  2020-07-27       Impact factor: 2.145
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.